Drug Trial News

RSS

Clinical trials to test safety of 3K3A-APC in patients with ischemic stroke

Clinical trials start this week for a stroke drug initially created by a team led by scientists at The Scripps Research Institute and the University of Southern California (USC), and further developed by biotech company ZZ Biotech.

9 Aug 2012

Combination of two existing pharmaceutical drugs shows promise against cocaine addiction

A fine-tuned combination of two existing pharmaceutical drugs has shown promise as a potential new therapy for people addicted to cocaine—a therapy that would reduce their craving for the drug and blunt their symptoms of withdrawal.

9 Aug 2012

Data from IMUC’s ICT-107 Phase I trial on glioblastoma multiforme accepted for publication

ImmunoCellular Therapeutics announced today that clinical data from its Phase I trial of ICT-107 was accepted for publication, and is currently in the online edition of the prestigious medical journal Cancer Immunology, Immunotherapy.

9 Aug 2012

Active Biotech, Teva to commence third Phase III study of laquinimod for RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech provided today an update on the clinical development program of once-daily oral laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS).

9 Aug 2012

Amgen announces decision to stop ganitumab Phase 3 trial in advanced pancreatic cancer

Amgen today announced a decision to stop the ganitumab (AMG 479) Phase 3 GAMMA (Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas) trial following the recommendation of an independent Data Monitoring Committee (DMC) overseeing the trial.

9 Aug 2012

Lightlake announces final data from naloxone nasal spray Phase II study on Binge Eating Disorder

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today compelling final data from a Phase II study of the Company's proprietary opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED).

9 Aug 2012

Omeros completes enrollment in first of two OMS103HP Phase 3 meniscectomy trials

Omeros Corporation today reported the completion of enrollment in the first of two planned Phase 3 clinical trials evaluating OMS103HP in patients undergoing arthroscopic partial meniscectomy surgery.

8 Aug 2012

HCRI announces successful completion of randomization in DAPT Study

The Harvard Clinical Research Institute (HCRI) announced today the successful completion of randomization in the DAPT Study, with the total number of patients randomized exceeding the upper goal set for the Study.

8 Aug 2012

Patients in clinical trials of new targeted cancer therapies appear to have lower risk of side-effects

Patients in early clinical trials of new-style targeted cancer therapies appear to have a much lower risk of the most serious side-effects than with traditional chemotherapy, according to a new analysis.

8 Aug 2012

Corticosteroids show no clinical benefit in treating acute sinusitis

Corticosteroids, frequently prescribed to alleviate acute sinusitis, show no clinical benefit in treating the condition, according to a randomized controlled trial published in CMAJ.

8 Aug 2012

UMass Medical, Serum Institute of India partner on anti-rabies monoclonal antibody pivotal trial

A pivotal clinical trial for an anti-rabies human monoclonal antibody (RMAb) being developed through a collaborative partnership between MassBiologics of the University of Massachusetts Medical School and the Serum Institute of India, Ltd., is starting to enroll patients.

8 Aug 2012

Clinical trial targets breast cancer cells by injecting trastuzumab directly into the spinal fluid

In two to five percent of women with breast cancer, tumor cells migrate into the spinal fluid invading the tissue surrounding the brain and spinal cord called the meninges. While a rare complication, the condition is challenging because there is no agreed-upon standard of treatment, leaving little hope for patients affected. Northwestern Medicine- researchers are currently examining a novel approach to delivering an FDA approved drug that they hope will advance research for this type of cancer and lead to discoveries that may improve outcomes in the future.

7 Aug 2012

Novartis’ pasireotide offers symptom relief for patients with advanced neuroendocrine tumors

A researcher at Moffitt Cancer Center and his international team of colleagues have reported study results on a novel multireceptor-targeted somatostatin analogue called pasireotide (SOM230) manufactured by Novartis Pharma AG.

7 Aug 2012

Adalimumab effective in maintaining remission in pediatric patients with Crohn's disease

Adalimumab (an anti-tumor necrosis factor [TNF] antibody) is effective in maintaining remission in certain pediatric patients with Crohn's disease, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.

7 Aug 2012

Creatine may fight major depression in women

Women battling stubborn major depression may have a surprising new ally in their fight—the muscle-building dietary supplement creatine.

7 Aug 2012

Topline results from Janssen bapineuzumab Phase 3 trial on mild-to-moderate Alzheimer's

Pfizer Inc. announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI)-led Phase 3 trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer's disease who do not carry the ApoE4 (apolipoprotein E epsilon 4) genotype (Study 301).

7 Aug 2012

Curemark receives FDA clearance for enrollment of children aged 9-12 in CM-AT study for autism

Dr. Joan Fallon, founder and CEO of Curemark, a Rye, New York-based drug research and development company focused on the treatment of Autism and neurological diseases, today announced that the company has received clearance from the Food and Drug Administration (FDA) to commence direct enrollment of children 9-12 years of age into its open-label extension study of CM-AT for children with Autism.

6 Aug 2012

Novel multireceptor-targeted somatostatin analogue found effective against neuroendocrine tumors

6 Aug 2012

Rexahn announces completion of RX-3117 exploratory Phase I clinical trial in cancer patients

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed its exploratory Phase I clinical trial of RX-3117 in cancer patients.

6 Aug 2012

Nanobiotix, PharmaEngine partner to commercialize NBTXR3 for soft tissue sarcoma

PharmaEngine, Inc. announced today the execution of an exclusive license and collaboration agreement with France-based Nanobiotix S.A. for the development and commercialization of NBTXR3, currently being investigated in a phase I study with soft tissue sarcoma patients.

6 Aug 2012

Drug Trial News

Clinical trials to test safety of 3K3A-APC in patients with ischemic stroke

Combination of two existing pharmaceutical drugs shows promise against cocaine addiction

Data from IMUC’s ICT-107 Phase I trial on glioblastoma multiforme accepted for publication

Active Biotech, Teva to commence third Phase III study of laquinimod for RRMS

Amgen announces decision to stop ganitumab Phase 3 trial in advanced pancreatic cancer

Lightlake announces final data from naloxone nasal spray Phase II study on Binge Eating Disorder

Omeros completes enrollment in first of two OMS103HP Phase 3 meniscectomy trials

HCRI announces successful completion of randomization in DAPT Study

Patients in clinical trials of new targeted cancer therapies appear to have lower risk of side-effects

Corticosteroids show no clinical benefit in treating acute sinusitis

UMass Medical, Serum Institute of India partner on anti-rabies monoclonal antibody pivotal trial

Clinical trial targets breast cancer cells by injecting trastuzumab directly into the spinal fluid

Novartis’ pasireotide offers symptom relief for patients with advanced neuroendocrine tumors

Adalimumab effective in maintaining remission in pediatric patients with Crohn's disease

Creatine may fight major depression in women

Topline results from Janssen bapineuzumab Phase 3 trial on mild-to-moderate Alzheimer's

Curemark receives FDA clearance for enrollment of children aged 9-12 in CM-AT study for autism

Novel multireceptor-targeted somatostatin analogue found effective against neuroendocrine tumors

Rexahn announces completion of RX-3117 exploratory Phase I clinical trial in cancer patients

Nanobiotix, PharmaEngine partner to commercialize NBTXR3 for soft tissue sarcoma

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News